ArticleIranian journal of basic medical sciences2026
Anti-inflammatory and anti-oxidant efficacy of origanum species and honey in a rat model of COPD.
Article in Iranian journal of basic medical sciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objectives: Chronic obstructive pulmonary disease (COPD) is a progressive airway condition characterized by chronic inflammation, oxidative stress, and tissue remodeling. Conventional treatments offer limited benefits in halting disease progression, prompting increased interest in natural agents with antioxidant and anti-inflammatory properties. This study aimed to evaluate the therapeutic effects of Materials and Methods: Thirty-eight female Wistar albino rats were divided into five groups: Control, COPD, Results: Conclusion: The findings indicate that Origanum species and honey may have therapeutic potential for COPD by modulating inflammation, the immune response, and the protease-antiprotease balance. Further molecular and clinical studies are warranted.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.